272 Capital LP Has $1.54 Million Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

272 Capital LP lowered its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO - Free Report) by 61.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 592,712 shares of the medical instruments supplier's stock after selling 943,108 shares during the period. Harvard Bioscience makes up 1.7% of 272 Capital LP's investment portfolio, making the stock its 20th biggest holding. 272 Capital LP owned about 1.36% of Harvard Bioscience worth $1,543,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in HBIO. Corsair Capital Management L.P. acquired a new position in Harvard Bioscience in the 3rd quarter valued at approximately $63,000. Advantage Alpha Capital Partners LP bought a new stake in shares of Harvard Bioscience during the third quarter valued at approximately $64,000. Landscape Capital Management L.L.C. bought a new stake in shares of Harvard Bioscience during the third quarter valued at approximately $50,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Harvard Bioscience by 19.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 180,006 shares of the medical instruments supplier's stock valued at $484,000 after purchasing an additional 29,607 shares in the last quarter. Finally, Avior Wealth Management LLC lifted its position in Harvard Bioscience by 1,118.1% in the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 13,373 shares during the period. Institutional investors own 80.87% of the company's stock.

Harvard Bioscience Price Performance

Harvard Bioscience stock remained flat at $2.20 on Friday. 83,508 shares of the company's stock traded hands, compared to its average volume of 179,460. Harvard Bioscience, Inc. has a 12-month low of $1.99 and a 12-month high of $5.56. The stock has a market capitalization of $95.96 million, a price-to-earnings ratio of -6.67 and a beta of 1.31. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The firm has a 50 day simple moving average of $2.40 and a two-hundred day simple moving average of $2.78.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.